Search Articles — Sudonull

https://sudonull.com/psa-plugin-for-intellij-custom-autocomplete

Set up project autocomplete and GoTo in IntelliJ via PSA. PSI context analysis by script. Instructions for middle/senior dev. Install and test.

https://ymaho.com/intellia-crispr-therapy-fda-filing-for-lonvo-z-for-hae

Intellia has filed the world's first application for an in vivo CRISPR therapy, lonvo-z, for hereditary angioedema (HAE). 87% reduction in attacks, 62% attack-free. Risk, market, and forecast analysis. Read.

https://ymaho.com/intellia-crispr-therapy-phase-3-data-on-edema-breakthrough

Intellia presented long-awaited phase III data of CRISPR therapy lonvo-z for hereditary angioedema: 87% reduction in attacks, 62% of patients attack-free. Learn about the breakthrough in in vivo genome editing.

https://ymaho.com/crispr-therapy-hae-phase-3-data-from-intellia-at-eaaci-2026

Intellia presented the long-awaited results of phase 3 of CRISPR therapy lonvoguran ziclumeran for hereditary angioedema. Reduction of attacks by 87%, 62% of patients without therapy. Learn more.

https://ymaho.com/crispr-therapy-in-vivo-intellia-study-87-efficacy-in-hae

Phase 3 HAELO: single CRISPR infusion reduced hereditary angioedema attacks by 87% vs placebo. First in vivo therapy on the verge of registration. Details, insights, forecasts.